{"name":"Immunic, Inc.","slug":"immunic","ticker":"IMUX","exchange":"NASDAQ","domain":"imux.com","description":"Immunic, Inc. (IMUX) is a clinical-stage immunology biotech company focused on developing therapies for autoimmune and inflammatory diseases. The company's top drugs include vidofludimus calcium (IMU-838) and itacitinib (IMU-838). Immunic, Inc. is a relatively small player in the immunology biotech space.","hq":"New York, NY","founded":0,"employees":"","ceo":"Daniel Vitt","sector":"Clinical-Stage Immunology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":81983000,"netIncome":-97172000,"cash":15483000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"IMU-838 patent cliff ($0.0B at risk)","drug":"IMU-838","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Immunic Announces FDA Clearance of IND for IMU-935","summary":"Immunic, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IMU-935, a novel, orally administered, small molecule inhibitor of the sphingosine 1-phosphate receptor 1 (S1PR1).","drugName":"IMU-935","sentiment":"positive"},{"date":"2022-03-15","type":"earnings","headline":"Immunic Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Immunic, Inc. reported its financial results for the fourth quarter and full year 2021, highlighting a net loss of $24.4 million and $104.5 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2021-08-10","type":"deal","headline":"Immunic Announces Collaboration with the University of California, San Francisco (UCSF)","summary":"Immunic, Inc. announced a collaboration with the University of California, San Francisco (UCSF) to develop novel therapies for autoimmune and inflammatory diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9sVlJkVm9mWjZmVXMzUGJrSWVmX2ZaTFdHSzV5UThEMDZ0aUlNaWRtSXg2Zl9qZ3VHSmZqRXRlVnFsaThmU1FRQm1aQlZORXJqdGc?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance UK","summary":"Immunic, Inc. (IMUX) stock price, news, quote and history - Yahoo Finance UK","headline":"Immunic, Inc. (IMUX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1BNXJXbXFyWUQ3YTFGZk1OWmJjNUdveWExSzdaSDQzZHVQTEFyMVMzb3lIUjRTeldqU3RzZUhpcXhLNDhiZXB1WEgwekVPT2IwbGJGZXdyQkZDTXhOVUxYNWxBdnMtZGx0amwtcThB?oc=5","date":"2026-04-04","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan","headline":"If You Invested $1,000 in Immunic Inc (IMUX)","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOTERLN3dVSHhKeHQyZzROWHVlZkpTZDgwWll1emFjY1dBYnhPTk5TTkNVWHVLN1JLdFpPT29xaHFFNDJwMF9oN2V2VkdNR1FKc3h1aHNjSEVxN3NOaHNJWGlQZTdiU3VnUHZMcHozb2wzREdqWXE4ekFjcXVfeFA0cC1lajAtVTVmaFBqRmFCT3V4VWhYMXp3SGJmUjRJSWpfREk5Yng2TUxEbW1USXlQSTdsTlNlVF9kZ2NtNGNOOW5MdWU1SzF5M1BURFVwOWR6OGlXUW94eTFmYjZOVGt6d2ZQeDhxYktVRUJBUklEZ1BRVnk4alpuMnBPYTY1Zw?oc=5","date":"2026-03-31","type":"pipeline","source":"Sahm","summary":"Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - Sahm","headline":"Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQMWFSa3h5Z2NlVS0zZzZpR0xBcDhsU2tZdjBCX1o4VVJTaDVfNUs4WHBWa0dtMGd0U3M5OU9xeE9udk1LVmFLbjI4VGtRSXZHNVhmd1lyLUV0X0FrLW11a0N4S09lVDhXVndVWHNNSW5OQzdjbGZSYU82cXFUcG16UFJGRDdUbGFvMXpIMHhZSmhFWnpqU2loMHliZ1g4SXJMei1PNlNOckhsNTBvb1NmczV4djlTcE5uenp3V1h0a001bFB5VTRTSWNGUWdLdw?oc=5","date":"2026-03-03","type":"pipeline","source":"proactiveinvestors.com","summary":"Immunic to present at healthcare investor conferences in March | NASDAQ:IMUX - proactiveinvestors.com","headline":"Immunic to present at healthcare investor conferences in March | NASDAQ:IMUX","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOdy1IR0tvZ25HUGowMjByem5DQzdpYWt4WWpIUEZwMGNueG5LSmtBNXJMWFFkN0pfV3VuSnBlX0UxOVZWdllZLXRQb1VjbVg3eXpLd0ZrMUlySzc3NFhQYmRzQ2xLS1hCMmNPSGU4SWpYUHF3MV9icDI4RnNKeEludUZJMWdHYnVPMVZBZWp1T2l3NkZZakRPTjVnWmlZbk83bm13N3RjdXhxbk9oVFpVdWhubzQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-17","type":"pipeline","source":"simplywall.st","summary":"We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate - simplywall.st","headline":"We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQd25fX3FiekZ0VTQ1TDJqODE2TVk1UlNFUWUyNVpKZ0VWY3VBWlF4ekxmN1B3eXlyeHhjUWFlcDhTNzdfTzZDV1RMZFpvZTR2Zkg2S0FTNkZaSHY5MFhCdmxoRmVITFNHVGRUUktvSHJiYU90YjVxSXlRYXVqRWlrYTVFbS1pX1dubFVWTXEwUU9iT0t4cUdRME1WNXFLalk0MXBIbGx3dGxHODdvNWhGY1lRRGFEQk1LNUFGOU9qek1iaXBIMXpR?oc=5","date":"2025-10-01","type":"pipeline","source":"PR Newswire","summary":"Immunic to Participate in Scientific and Investor Conferences in October - PR Newswire","headline":"Immunic to Participate in Scientific and Investor Conferences in October","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOaV96UUh2cmtYT3VkN21KN2d4b1JyQ0FFTUo2UGtUaHZLOTBEYzRsdTA5MlNYbW9KU1MzcF9hZjItc3ZSRHVYT1N1VVFoYlFYLXEwdjE5QTNBdENBNUVqZGJsZ3BtOG1WZDV5YUlOcW9fdWFIcFBUTDVtWXZBc01IMGhOQ2trcTN2RlVlVFl5Qzg0TWNxMzVLOHd3VEpIN1QxMWNoU1JQYzZwNk9mZmJVaWxxN1B0LW1qRzFMVWNfZmxNR2hXMzFxc3l4WFBVSG9XVUppaUt4NjV5M0JWaktIZ1o3UFdvaGJqeG10Rm1nbmFOZi1oeUFfaFVfVHdZTW9NZzhfWDEyeVNQbnAzTGd2OFo3ZDJqSFAxeXVlcTI4STZiSGZSckE?oc=5","date":"2025-09-09","type":"patent","source":"PR Newswire","summary":"Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PR Newswire","headline":"Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNWFQajFjSFZRbkxrZmduTWw5REx0REM0dDBQdFdyeFNJNTlmcDBkNXJLMWZpdTIzdVR2U0ZJWFlOU1ZtdjZ5WWdpYThzcGRFeFJsR3VPUUhVNHRnOWxZMEFKMmtnemk0LU52UmxXdk1aZHJGeTczQlJsV2pSUnFtNjNpREpVNWZiTVN1cjBYSFpxMWRWVVdYdlcyMnZWYlFKQjByaEN5TVlHNTJsYm5GUkRUeU9FT1BJSWYw?oc=5","date":"2025-04-28","type":"trial","source":"Seeking Alpha","summary":"Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha","headline":"Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-16","type":"pipeline","source":"simplywall.st","summary":"Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st","headline":"Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRGVnNFhzRjFpczRqSS1lS2NFVU1rY0JhR0dCcGF1MU4ya0NWUGJiWVNiclpraExWRFZPTnJEZVpJSmZJLTdCTnU0RHQzQk95TWZUYnJxNjVjR0RxRHRBR21Fd3V1Ni1NN2VIb3ZMeWM3MVpKV0ZTS1hadlFpcUpSbzEtbGNjaXRR?oc=5","date":"2024-07-24","type":"pipeline","source":"citybiz","summary":"Immunic Appoints Simona Skerjanec to Board - citybiz","headline":"Immunic Appoints Simona Skerjanec to Board","sentiment":"neutral"}],"patents":[{"drugName":"IMU-838","drugSlug":"vidofludimus-calcium","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celgene Corporation","Gilead Sciences, Inc.","Pfizer Inc."],"therapeuticFocus":["Autoimmune Diseases","Inflammatory Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":81983000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-97172000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":15483000,"cashHistory":[],"totalAssets":24052000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}